Bionano Genomics, Inc.

Bionano Genomics, Inc. Earnings Recaps

BNGO Health Care 3 recaps
Q1 2026 May 14, 2026

Bionano’s shares fell 0.8% after earnings, reflecting investor caution despite modest growth in consumable revenues and improved reimbursement codes; softness in software revenue and ongoing execution risks likely weighed on sentiment.

Key takeaways
  • Q1 2026 flow cell sales reached a record 8,178 units, up 17% year-over-year, with flow cells sold to existing customers up 21% YoY.
  • Consumable revenue grew 20% year-over-year to $3.9 million, signaling traction in routine users and OGM focus.
  • Software revenue declined sharply by 40% year-over-year to $1.2 million due to a large prior-year sale that supplied customers through 2026.
  • Other revenue increased 36% year-over-year to $1.6 million, reflecting a higher proportion of recurring revenues.
  • Two significant reimbursement milestones took effect, increasing payment rates for key CPT codes by up to 47%, potentially improving long-term adoption economics.
Full recap
Q3 2025 Nov 14, 2025

Bionano reported a strong third quarter in 2025, achieving $7.4 million in revenue, representing a 21% year-over-year increase, driven by higher utilization among routine users of its optical genome mapping solutions.

Key takeaways
  • Total revenue rose 21% year-over-year, with core revenues up 12% after adjusting for discontinued services.
  • Non-GAAP gross margin improved significantly to 46%, up from 26% in Q3 2024.
  • Non-GAAP operating expenses decreased 40% year-over-year to $9.7 million, showcasing effective cost management.
  • Sold a record 8,390 flow cells, reflecting 7% growth and increased utilization by existing customers.
  • Cash position strengthened to $31.8 million following a $10 million public offering, extending the cash runway into 2026.
Full recap
Q2 2025 Aug 15, 2025

Bionano's Q2 2025 results reflect strategic progress with a 5% adjusted revenue decline despite a robust 17% year-over-year increase in flowcell sales, driven by routine user engagement.

Key takeaways
  • Total revenue for Q2 2025 was $6.7 million, a 13% decline from Q2 2024, but a 5% decrease when excluding discontinued services.
  • Flowcell sales surged 17% year-over-year, indicating strong demand within the routine user base.
  • Non-GAAP gross margin improved significantly to 52%, up from 35% in the same quarter last year.
  • Operating expenses were reduced by 53% year-over-year, totaling $8.8 million in Q2 2025.
  • The installed base of optical genome mapping systems remains stable at 378, with 16 new systems installed in the first half of 2025.
Full recap